Active, not recruitingPhase 2NCT02682641
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Eva Giné, MDHospital Clinic of Barcelona
- Intervention
- IBRUTINIB(drug)
- Enrollment
- 50 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2016 – 2029
Study locations (15)
- Hospital Clínic de Barcelona, Barcelona, Barcelona, Spain
- Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain
- Hospital Universitario Vall d'Hebron, Barcelona, Barcelona, Spain
- Institut Català d'Oncologia, Barcelona, Barcelona, Spain
- Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain
- Hospital Universitario de Burgos, Burgos, Burgos, Spain
- Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
- Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
- Hospital Universitario Ramon y Cajal, Madrid, Madrid, Spain
- MD Anderson Cancer Center, Madrid, Madrid, Spain
- Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
- Hospital Costa del Sol, Marbella, Málaga, Spain
- Hospital Universitario Virgen del Rocio, Seville, Sevilla, Spain
- Hospital Clínico de Valencia, Valencia, Valencia, Spain
- Hospital Universitario Clinico de Salamanca, Salamanca, Spain
Collaborators
Janssen-Cilag, S.A.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02682641 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center